Shield Reports on H1 Business Update

23 Jul 2018

Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, with an initial focus on addressing iron deficiency with its approved product, Feraccru®, today announces a business update following progress made in H1 2018.

Following the Company’s detailed analyses of the positive data from the placebo-controlled period of the AEGIS-CKD study, we completed a planned pre-NDA submission meeting with the FDA at which we presented the positive AEGIS-CKD study results together with a broader discussion regarding the Company’s intention to file an NDA for Feraccru in 2018.

You can read the full press release here.

Back to news